---
schema_version: "secwatch.filing_event.v1"
accession: "0001575872-23-000629"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T13:37:28.934320+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# TradeUP Acquisition amends stock purchase agreement; Estrella to issue 250K preferred shares as commitment fee

## Summary
- Amendment to Common Stock Purchase Agreement with White Lion Capital, dated April 26, 2023.
- Commitment fee changed: Estrella Biopharma to issue 250,000 Series A preferred shares ($250,000 value) to White Lion immediately prior to merger closing.
- Amendment modifies Sections 7.1(v) and 10.1(ii) of the original agreement; all other terms unchanged.

## SEC filing metadata
- accession: 0001575872-23-000629
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000157587223000629/0001575872-23-000629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000157587223000629/uptd-20230426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001575872-23-000629
- JSON: https://secwatch.observer/filing/0001575872-23-000629.json
- Plain text: https://secwatch.observer/filing/0001575872-23-000629.txt

## Key facts
- Material Agreements
  Estrella Immunopharma, Inc. amended Amendment to the Common Stock Purchase Agreement with White Lion Capital, LLC valued at $250,000 (effective 2023-04-26).
  - Action: amendment
  - Agreement: equity purchase
  - Counterparty: White Lion Capital, LLC
  - Value: $250,000
  - Effective: 2023-04-26
  source text: Pursuant to the Amendment, the Company agrees that it will, immediately prior to the closing of the proposed business combination with Estrella Biopharma, Inc. (“Estrella”), cause Estrella to issue to White Lion an aggregate of 250,000 shares of Estrella’s Series A preferred stock, par value $0.0001 per share, which the parties have acknowledged has a value of $250,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1844417/000157587223000629/0001575872-23-000629-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.